-
Sulforaphane Workflows for Redox and NLRP3 Studies
2026-09-22
Build a translational Sulforaphane workflow that connects Nrf2-linked oxidative stress response studies with NLRP3 inflammasome assays, cell-cycle profiling, and apoptosis measurements. The approach separates literature-backed mouse dosing from practical cell-culture optimization so researchers can compare mechanisms without overextending preclinical conclusions.
-
3X FLAG Peptide for Protein Workflows
2026-09-22
The 3X (DYKDDDDK) Peptide combines a compact, hydrophilic epitope with strong anti-FLAG recognition for recombinant protein capture, detection, and structural workflows. Its value is especially clear when studying proteins such as spartin, where matched purification, functional assays, and localization controls are needed to separate lipid-transfer activity from organelle targeting.
-
Cabamiquine Pharmacodynamics: Fast Arrest, Slow Clearance
2026-09-21
The reference study separates cabamiquine-induced translational arrest from subsequent parasite killing, showing that protein synthesis stops within hours while irreversible death develops over a longer interval. Its orthogonal in vitro assays help explain the clinically observed lag between treatment, fever improvement, and parasite clearance.
-
Q-VD-OPh for Mitochondrial Apoptosis Assays
2026-09-21
Q-VD-OPh combines broad, irreversible caspase activity inhibition with cell and brain permeability, making it useful for apoptosis research, post-thaw recovery, and neurodegeneration models. This guide shows how to pair the compound with mitochondrial mRNA imaging to distinguish upstream organelle remodeling from downstream caspase execution.
-
Cy5.5 NHS Ester for Mapping OA Nanogene Delivery
2026-09-20
Cy5.5 NHS ester (non-sulfonated) offers a near-infrared strategy for tracking amine-bearing delivery components in aged osteoarthritis models. This article connects covalent labeling chemistry with spatial assay design for evaluating hydrogel retention, nanoparticle transport, and translational imaging limits.
-
CD36 Lipid Sensing Drives Immune Escape in AML
2026-09-19
Guo and colleagues identify a CD36-dependent, non-canonical lipid-sensing program that enables AML cells to suppress T-cell activity and resist decitabine therapy. The study separates this immune function from lipid oxidation and supports statin-mediated lipid restriction as a strategy for improving hypomethylating-agent efficacy.
-
MK-1775 Workflow for Checkpoint Studies
2026-09-18
Use MK-1775 to interrogate Wee1-dependent G2 control, distinguish growth arrest from true cell killing, and test chemotherapy sensitization in p53-deficient models. This workflow combines phospho-CDC2 readouts, time-resolved viability measurements, and practical troubleshooting for more interpretable cancer research data.
-
EZ Cap™ Human PTEN mRNA (ψUTP) Workflow
2026-09-18
Use EZ Cap™ Human PTEN mRNA (ψUTP) to build controlled PTEN-expression experiments in mammalian cells, from pathway assays to nanoparticle-enabled cancer models. Its Cap 1 structure, pseudouridine modification, and poly(A) tail support efficient translation while helping researchers investigate PI3K/Akt signaling and therapeutic resistance.
-
Pexmetinib (ARRY-614): State-Aware Cytokine Research
2026-09-17
A translational perspective on Pexmetinib (ARRY-614) as a dual p38 MAPK and Tie2 inhibitor, integrating cytokine assay design, conformational kinase biology, hematologic research, and practical workflow guidance.
-
Sex Differences in Angiotensin II Hypertension
2026-09-17
Xue, Pamidimukkala, and Hay used telemetry in conscious mice to show that chronic angiotensin II produces a substantially larger blood-pressure increase in males than females. Gonadectomy, baroreflex testing, and ganglionic blockade further linked this divergence to sex-dependent hormonal and sympathetic regulation rather than baseline blood pressure alone.
-
Zosuquidar: A Decision Framework for P-gp Assays
2026-09-16
Zosuquidar (LY335979) is a selective P-glycoprotein modulator for dissecting efflux-driven drug resistance. This guide connects cancer sensitization assays with disease-state pharmacokinetic insights while clarifying experimental boundaries and controls.
-
In Vitro Drug Response Metrics in Cancer Research
2026-09-16
Hannah R. Schwartz’s 2022 dissertation shows that relative viability and fractional viability are complementary, not interchangeable, measures of anticancer drug response. Its central practical contribution is a framework for separating proliferative inhibition from cell killing, improving interpretation of checkpoint-targeted and combination-treatment experiments.
-
Electroporation for CRISPR/Cas9 Editing in Mouse Zygotes
2026-09-15
Hashimoto and Takemoto developed an electroporation workflow that delivers CRISPR/Cas9 RNAs into mouse zygotes without removing the zona pellucida. By optimizing pulse strength and repetition, the study established a scalable alternative to microinjection for knockout and ssODN-mediated knock-in experiments.
-
MYC2–LBD40/42 Control of Tomato Gray Mold Defense
2026-09-15
This study identifies a MYC2–LBD40/42–CRL3BPM4 module that fine-tunes tomato resistance to Botrytis cinerea by balancing immune activation with growth-related costs. Its central advance is the demonstration that LBD repressors act as reversible brakes: SlMYC2 induces them, while SlBPM4-dependent degradation releases defense activity.
-
Fluorescein TSA Fluorescence System Kit in Spatial Biology
2026-09-14
Spatial proteomics is moving toward cell-type resolution, but translational teams still need practical ways to validate low-abundance targets in intact tissue. This thought-leadership article explains how tyramide signal amplification complements proximity proteomics, outlines validation and workflow strategy, and positions the Fluorescein TSA Fluorescence System Kit as a targeted bridge between discovery-scale profiling and spatially resolved biological interpretation.